By Steve Usdin
Contributing Editor

BETHESDA, Md - An FDA advisory committee on Friday voted 5 to 3 to recommend against approval of The Medicines Co.'s Hirulog (bivalirudin) anticoagulant for patients undergoing percutaneous transluminal coronary angioplasty (PTCA) for the treatment of unstable angina.